COVID-19 news is changing rapidly and we are all trying to stay on top of the latest medical information from trusted sources. Join experts in the medical field for free CME webinars covering what we know about the coronavirus outbreak.
Dr. Paul Auwaerter discusses the latest developments in COVID-19 vaccines. Topics: *Breaking news: the latest on the new Johnson & Johnson vaccine *Are variants impacting vaccine performance? *Explanations for the recent decrease in cases *The better vaccination strategy: one dose or two doses?
Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Enduring Internet Activity
The enduring material will be available from February 24, 2021 to February 24, 2022. Jointly provided by Postgraduate Institute for Medicine, DKBmed and the Institute for Johns Hopkins Nursing (IJHN)Estimated time to complete this activity: 15 minutesFor CME questions, please visit www.pimed.com. For CNE questions, please contact the IJHN office at [email protected]
This activity is intended for health care providers in the care of patients with COVID-19. This educational activity is supported by independent medical educational grants from Gilead Sciences, Inc., Regeneron Pharmaceuticals, Inc., and Eli Lilly and Company.
After completing this activity, the participant should be better able to:
Describe real-world evidence of efficacy of COVID-19 vaccines
Discuss implications of emerging variants on vaccine dosing strategies
Paul G Auwaerter, MD, MBA, FIDSA
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until February 24, 2022. PAs should only claim credit commensurate with the extent of their participation.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.Accreditation StatementThe Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.Designation StatementThis 0.25 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Statements will be awarded for this educational activity February 24, 2022.Policy on Privacy and ConfidentialityPlease see final activity for the policy on privacy and confidentiality that relates to this internet activity.Disclosure of Conflicts of InterestPostgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.It is the policy of the Institute for Johns Hopkins Nursing that the presenter and provider globally disclose conflicts of interest. The IJHN has established policies that will identify and resolve conflicts of interest prior to this educational activity.Faculty / Presenter Reported Financial RelationshipPaul G. Auwaerter, MD, MBA, FIDSA
Scientific Advisor: DiaSaorin, Shionogi Inc.
Ownership Equity: JNPPlanners and ManagersThe PIM planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose. The IJHN Nurse Planner has nothing to disclose.Media
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of the IJHN name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of February 24, 2021 through February 24, 2022, participants must read the learning objectives and faculty disclosures and study the educational activity. In order to receive nursing contact hours, participants must also complete and submit an evaluation.If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
Include minimum hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity.